

27 June 2025

Treatment of endometrial cancer

Q1. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 1st Jan 2025 and 31st Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Dostarlimab (Jemperli)	<5
1.2 Pembrolizumab(Keytruda) Combination= Lenvatinib+Pembrolizumab	Mono <5 Combination 5
1.3 Lenvatinib(Lenvima) Combination= Lenvatinib+Pembrolizumab	Mono <5 Combination 5

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

Q2. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 1st Jan 2025 and 31st Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Dostarlimab monotherapy	<5
2.2 Dostarlimab in combination with Chemotherapy	<5
2.3 Pembrolizumab monotherapy	<5
2.4 Pembrolizumab + Lenvatinib in combination	5
2.5 Lenvatinib monotherapy	<5

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.